Given the role of oxidative stress in PD pathogenesis and off-target side effects of currently available drugs, several natural phytochemicals seems to be promising in the management of PD. Here, we tested the hypothesis that scopoletin, an active principle obtained from Morinda citrifolia (MC), efficiently quenches oxidative stress through DJ-1/Nrf2 signalling and ameliorates rotenone-induced PD. Despite reducing the oxidative stress, administration of MC extract (MCE) has lessened the protein aggregation as evident from decreased levels of nitrotyrosine and α-Synuclein. In vitro studies revealed that scopoletin lessened rotenone-induced apoptosis in SH-SY5Y cells through preventing oxidative injury. Particularly, scopoletin markedly up-regulated DJ-1, which then promoted the nuclear translocation of Nrf2 and transactivation of antioxidant genes. Furthermore, we found that scopoletin prevent the nuclear exportation of Nrf2 by reducing the levels of Keap1 and thereby enhancing the neuronal defence system. Overall, our findings suggest that scopoletin acts through DJ-1 mediated Nrf2 signalling to protect the brain from rotenoneinduced oxidative stress and PD. Thus, we postulate that scopoletin could be a potential drug to treat PD.
Introduction
Although the causal mechanisms of Parkinson disease (PD) remain elusive, excess production of reactive oxygen species (ROS), mitochondrial dysfunction, neuro-inflammation and environmental toxins are reported to promote the loss of dopaminergic neurons in PD [1] .
Oxidative stress has been shown to induce misfolding, aggregation and accumulation of such aggregates leading to the pathogenesis of many neurodegenerative diseases including PD [2] .
Intracellular inclusions known as Lewy Bodies (LBs) are regarded as a hallmark of common pathological manifestation in both familial and sporadic PD patients with α-Synuclein (α-Syn) serving as the main component of LB [3] . α-Syn is natively unfolded and is prone to form fibrils during oxidative stress [4] , indicating that redox signalling may play a significant role in the aggregation of α-Syn.
Previous studies have reported that loss of antioxidant defence aggravates PD progression [5, 6] . A key example includes DJ-1/PARK7, a molecular chaperone known to regulate Keap1-Nrf2 signalling, which is the primary sensor for reactive electrophiles activating Nrf2 nuclear translocation and transactivation of the antioxidant response element (ARE) in a battery of cytoprotective genes facilitating protection from oxidative stress pathogenesis [7] including experimental models of PD [8] . Thus, pharmacological activation of the Nrf2 in the brain is likely to preserve neuronal health. Therefore, exploration for therapeutic compounds with lesser neurotoxic effects that activates Nrf2 signaling would be promising to treat PD.
In this context, identifying potential principles from medicinal plants would be ideal as plant extracts have been reported to have several therapeutic benefits, due to the synergistic effect of various natural ingredients [9] . However, such plant sources have not been in clinical practice or in global market due to the lack of scientific validation. Here, we hypothesized that Morinda citrifolia extract (MCE) and scopoletin prevents rotenone-induced oxidative stress and apoptosis through activation of DJ1/Nrf2 signalling, thereby ameliorates PD in rats.
Materials and Methods

Animals, Intra-Nigral rotenone infusion and treatment
Adult male Sprague-Dawley rats were used in this study. 7.8 mm) and into the right Substantia Nigra Pars compacta (SNPc, AP: 5.0 mm; L: 2.0 mm; DV: 8.0 mm) at a flow rate of 0.2 µl/min using a Hamilton 26 gauge needle [10, 11] . The infusion needle was left in place for additional five minutes for complete diffusion of the drug. Sham controls were infused with DMSO and polyethylene glycol in the ratio of 1:1 during stereotaxic surgery. Two weeks post-surgery, rats in Group IV and V were treated with Levodopa (LD, 100mg/kg with 25mg/kg benserazide [12] ) and ethyl acetate extract of Morinda citrifolia fruit (MCE, 150mg/kg body weight), respectively, for the next 30 days. To determine the efficiency of intranigral-infusion of rotenone, animals were subjected to behavioural analysis [11] .
Statistical Analysis
Data are presented as mean ± standard error of mean (SEM) of the results obtained from the average of at least three to six independent experiments. Results were analysed by one-way analysis of variance (ANOVA) using the SPSS software package for Windows (Version 20.0; SPSS Inc., Chicago, IL, USA) and p values were determined using the Student-Newman-Keuls and least significant difference post hoc test. Differences among means were considered statistically significant when the p value was less than 0.05.
Results
Impact of MCE on nigrostriatal Tyrosine Hydroxylase (TH) immunoreactivity
Immunohistochemical localization of TH positive neurons in the striatum as well as the sunstantia nigra pars compacts (SNpc) of control and experimental rats are presented in 
MCE prevents rotenone induced oxidative stress by augmenting the antioxidant defence systems in experimental PD rats
Analyses of various oxidative stress markers indicated that MCE was an efficacious treatment to reduce oxidative stress in rotenone-induced PD rats. The levels of nitric oxide (NO), lipid peroxidation (LPO) and protein carbonyls (PC) were significantly increased (p<0.05) in the striatum of rotenone-infused PD rats and this was blunted in response to MCE treatment (Fig. 1C) . A significant decline (p < 0.05) in the activities of antioxidant enzymes, namely, superoxide dismutase (SOD), catalase, glutathione peroxidase (Gpx), glutathione reductase (GR) and glutathione-S-Transferase (GST) along with declined GSH was observed (Table 1 ) in the rotenone induced PD rats. However, upon supplementing with MCE, a significant augmentation in the activities of SOD, CAT and GST were observed with a maximum improvement in the SOD activity (36%) and reversed the GSH levels. As we observed a significant decline in Nrf2 protein levels, we further assayed transcript and protein levels for Nrf2 gene targets. Consistent with our observation of oxidative insult and Nrf2 pathway antagonism, rotenone treatment was associated with a prominent decline in the mRNA and protein (Fig. S1A-B ) levels of several ARE targets with a maximum decrease being observed in HO-1 (45%). MCE treatment significantly enhanced the levels of these proteins both at the transcriptional and translational levels by an average of 40%. The improved protein levels are reflected in the activities of these enzymes (Table 1) .
MCE protects from rotenone-induced protein aggregation
Rotenone infused Parkinsonian rats showed a significant (p<0.05) increase in the protein levels of iNOS and nitrotyrosine when compared with controls (Fig. 1D) . Treatment with MCE significantly ameliorated rotenone-mediated NO production through diminishing the levels of iNOS. As a result, we also found that MCE was particularly efficient in blocking the formation of nitrotyrosine adducts, which are the primary events in the process of protein aggregation that occurs in response to oxidative insults [2] . To further confirm the suppression of protein aggregation by MCE, we analysed the aggregation of α-Synuclein (α-Syn) by immuno-staining ( Fig. 2A-B) . Rotenone infused Parkinsonian rats exhibited a significant (p<0.05) increment in the protein levels of α-Syn by 79% (Fig. 2C) , which further aggravated the aggregation of α-Syn in these rats. While immunostaining showed a significant increase in α-Syn aggregation in the striatum of rotenone-induced rats which correlates with the increase in the nitrotyrosine levels, MCE treatment abolished these changes and significantly reduced the aggregation of α-Syn ( Fig. 2A-B) , suggesting suppression of oxidative stress is likely through MCE mediated augmentation of antioxidative signaling.
MCE induces Nrf2/ARE pathway and supress rotenone induced oxidative stress
Downregulation of the Nrf2/ARE pathway exacerbates oxidative stress which potentiates dopaminergic degeneration and pathogenesis of PD [13] . Thus, we further analysed the levels of Nrf2 and its interacting proteins to test the hypothesis that MCEmediated augmentation of antioxidative system occurs through activation of Nrf2/ARE signalling. Immunoblotting analysis revealed that MCE-treatment significantly rescued the levels of Nrf2 and reversed the rotenone-induced increase in Keap1 and Cullin3 (Fig. 3A) .
Next, we extended our immunoblotting analyses of total protein expression to nuclear and cytosolic fractions (Fig. 3B) . Our results confirmed that rotenone infusion significantly repressed the activation of Nrf2 as nuclear Nrf2 protein decreased in rotenone versus control rats. Hence, rotenone-infusion not only decreases total Nrf2 protein levels, but also impairs its nuclear translocation by augmenting cytosolic Keap1 levels. As such, supplementation with MCE significantly augmented the nuclear translocation of Nrf2 as evident from increased levels of nuclear Nrf2 (83%) by decreasing the nuclear Keap1 levels when compared with rotenone alone infused rats. cell-death, which was attenuated by pre-treating the cells with 30μM scopoletin for 3 hrs (Fig. 4A-B) . These data indicate that scopoletin protects SH-SY5Y from rotenone-induced cell death. As scopoletin prevented rotenone-induced cell death, we further assessed the regulation of Nrf2 signalling (Fig. 4C) . Along these lines, SH-SY5Y cells were pre-treated with 30µM scopoletin for 3 hours and both the un-phosphorylated (total/cytosolic form) and the serine 40 phosphorylated Nrf2 (pNrf2S40) levels were measured by immunoblotting.
Consistent with animal studies demonstrating that MCE improves nuclear levels of Nrf2, scopoletin augmented the nuclear translocation of Nrf2 as evident from the increased nuclear levels of pNrf2 (S40) (Fig. 4D) . This increase in the nuclear levels of Nrf2 may be attributed to the phosphorylation of Nrf2 by PKC-δ which is also augmented upon pre-treating with scopoletin. Concomitant with the animal studies, both the total and nuclear levels of Keap1 were significantly elevated in rotenone alone treated SH-SY5Y cells when compared with untreated control cells. Furthermore, rotenone treatment also increased the levels of E3 ubiquitin ligase Cullin3 by 46%.
Recent reports indicate that nuclear translocation of Nrf2 is not only mediated by phosphorylation by PKC-δ but also by intact DJ1, which binds and stabilizes the Nrf2 and favours its translocation to the nucleus [15] . While rotenone decreases the levels of DJ-1, scopoletin pre-treated cells showed an augmented expression of DJ-1 (46%), suggesting that DJ-1 may be vital for scopoletin-mediated neuroprotective effects. From these observations, it is clear that scopoletin augments the Nrf2/ARE pathway by increasing levels of DJ-1 and concomitantly prevents the cytosolic degradation of Nrf2.
Discussion
Parkinson's disease (PD) is the second most common progressive neurodegenerative disorder with increased oxidative stress being the key player of the pathogenesis. Therefore, increasing interest has been focused on identifying dietary supplements and phytoconstituents that can ameliorate oxidative stress mediated protein aggregation and cell death, thereby reversing the multi-faceted pathophysiological events underlying PD. Here, we investigated whether Morinda citrifolia (noni) fruit extract (MCE) attenuates rotenone-induced oxidative stress by activating the Nrf2-dependent antioxidant response. We elucidated the mechanism of action for scopoletin, a major compound present in the MCE, in vitro using SH-SY5Y cells and identified that the therapeutic effect of scopoletin is facilitated through activation of the DJ-1/Nrf2/ARE signalling cascade.
Recent reports have demonstrated that an imbalance of nitric oxide (NO) signalling underlies the incidence of oxidative stress in PD [2, 16] . Here, we have shown that MCE supplementation significantly abrogates rotenone mediated increase in NO and iNOS in the striatum of PD induced rats. These results provide evidence for the antioxidative potential of MCE in the brain. Although levodopa (LD), used as a positive control to treat rotenone-infused mice, seems to be protective in the current study, its chronic use might be detrimental as previous studies have shown that nitric oxide levels were increased in LD treated PD patients [17] . Therefore, use of a natural antioxidant like Morinda citrifolia or coadministered with LD might hold promising outcomes in PD.
As protein aggregation is a common event underlying neurodegenerative diseases including PD, wherein α-Synuclein comprises the bulk of Lewy bodies [18, 19] , we assessed whether the antioxidant capacity of MCE could supresses α-Synuclein aggregation. Indeed, MCE treatment attenuated the increase in α-Synuclein expression and aggregation following rotenone exposure. Consistent with the relationship between NO and α-Synuclein aggregate formation, the cytoprotective effects of MCE may be mediated though its impact on NO availability and tyrosine nitration [20] .
To combat oxidative insult, the intracellular defense is maintained through a variety of antioxidant enzymes and non-protein thiols such as glutathione (GSH) [21, 22] . In the current study, rotenone infusion resulted in a significant decline in striatal GSH content, and Previous reports have shown that DJ-1 stabilizes Nrf2 and promotes its nuclear translocation [25] . Intriguingly, mutations in DJ-1 are associated with risk of developing PD [26] . Hence, we further evaluated the effect of scopoletin on DJ-1 levels in SH-SY5Y cells.
We found that pre-treating SH-SY5Y cells with scopoletin rescued DJ-1 protein levels, subsequently conferring protection against rotenone induced oxidative stress. Therefore, Nrf2 stabilization and activation underlies the therapeutic potential for MCE and scopoletin to combat oxidative stress during PD pathogenesis.
Conclusion
Our findings provide evidence that MCE prevented α-synuclein aggregation through augmenting Nrf2-antioxidant signalling and suppressing oxidative stress. Notably, scopoletin, the active component from MCE seems to be responsible for stabilizing Nrf2/ARE pathway by augmenting the phosphorylation of Nrf2 and its nuclear translocation, in a DJ-1-dependent manner. Thus, we propose that DJ-1 might be a potential target for scopoletin-based therapeutic strategy against neurodegenerative diseases. 
